HR and breast cancer: International and French clinical guidelines recommend that, for patients with HR+, HER2−, early BC, adjuvant treatment includes endocrine therapy (ET) with or without chemotherapy (CT) (4–6); in real-world clinical practice in France, CT is used in approximately 44% of these patients (7).